Maruho introduces Mitchga SC injection 30mg vials, an antibody treatment for pruritus associated with atopic dermatitis (paediatric) and prurigo nodularis in Japan
Overview
Maruho Co., Ltd. announces that it has launched Mitchga subcutaneous (SC) injection 30mg vials (Japanese Accepted Name (JAN): Nemolizumab (genetical recombination), in Japan for the treatment of the following diseases only when existing treatment is insufficiently effective: pruritus associated with atopic dermatitis (children aged =6 and <13 years), prurigo nodularis (adults and children aged =13 years).
Nemolizumab Subcutaneous Injection
- The product is a vial for subcutaneous injection containing nemolizumab, a humanized anti- interleukin-31 (IL-31) receptor A monoclonal antibody discovered and developed by Chugai Pharmaceutical Co., Ltd., as an active ingredient.
- In September 2016, Maruho entered into a license agreement with Chugai to develop and market the product in the skin disease area for the Japanese market.
- • Maruho developed the product in Japan and acquired approval for manufacturing and marketing in March 2024, followed by the NHI drug price listing in May 2024, leading to the launch of the product.
About IL-31
- IL-31 is a cytokine that induces itch and is involved in the development of pruritus caused by atopic dermatitis.
- It has also been shown to induce itch in prurigo nodularis and to be involved in its pathogenesis.
- By competitively inhibiting the binding of IL-31 to its receptor, this product is expected to improve the pruritus and skin symptoms associated with atopic dermatitis (paediatric patients) and prurigo nodularis, thereby improving patients' Quality of Life (QOL).
Maruho Acquisition
In March 2022, Maruho acquired the world's first manufacturing and marketing approval for ""Mitchga subcutaneous injection 60mg syringes"" for the treatment of pruritus associated with atopic dermatitis in adults and children over 13 years old (only when existing treatment is insufficiently effective) in Japan. Maruho launched ""Mitchga subcutaneous injection 60mg syringes"" in August 2022 in Japan.
Maruho Efforts for Treatment
Maruho, specializing in dermatology, is committed to contributing to the smiles of patients suffering from itching caused by atopic dermatitis and patients suffering from prurigo nodularis by promoting the appropriate use of the product and ""Mitchga subcutaneous injection 60mg syringes."
